UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer.
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide.
Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally.
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of hematological malignancies and solid tumors.
Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally.
Acacia Pharma Group plc, a hospital pharmaceutical company, focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients in the United States and internationally.
MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally.
Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases.
ASIT Biotech S.A., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally.